<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02379676</url>
  </required_header>
  <id_info>
    <org_study_id>XC14MIMI0092k</org_study_id>
    <nct_id>NCT02379676</nct_id>
  </id_info>
  <brief_title>Effect of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation</brief_title>
  <official_title>Comparison of the Effects of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation in Patients With Prior Non-ST-segment Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiyuk Chang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of ticagrelor and clopidogrel on&#xD;
      endothelial dysfunction and vascular inflammation&#xD;
&#xD;
      Ticagrelor will lead to beneficial pleiotropic effects compared with treatment with&#xD;
      clopidogrel in patients receiving a drug-eluting stents (DES) during percutaneous coronary&#xD;
      intervention (PCI) for non-ST-segment acute coronary syndrome (NSTE-ACS) beyond 1 month after&#xD;
      the index event. Ticagrelor treatment will improve percent flow-mediated dilation (FMD)&#xD;
      values and reduces inflammatory gene expression on peripheral blood mononuclear cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study lies in whether ticagrelor improves endothelial&#xD;
      dysfunction compared to clopidogrel, measured by endothelium-dependent flow-mediated dilation&#xD;
      (FMD). The secondary objective is to demonstrate whether ticagrelor has an&#xD;
      anti-atherosclerotic effect compared to clopidogrel in terms of reducing systemic low-grade&#xD;
      inflammation. Endpoints are 1) difference of flow-mediated dilation values, and 2) messenger&#xD;
      ribonucleic acid (mRNA) expression measured by quantitative real-time reverse&#xD;
      transcription-polymerase chain reaction (qRT-PCR) of inflammation-associated key genes in&#xD;
      circulation monocytes between non-ST-segment acute coronary syndrome patients treated with&#xD;
      ticagrelor and clopidogrel.&#xD;
&#xD;
      Patients who agree to participate study are screened at Visit 1 (30 ~ 365 days after index&#xD;
      percutaneous coronary intervention). Patients with endothelial dysfunction defined as&#xD;
      screening flow-mediated dilation are randomly assigned at Visit 2 (0~7 days after screening&#xD;
      test). And then, patients should receive study drugs according to allocated groups from the&#xD;
      day of randomization. Ticagrelor 90mg twice daily or clopidogrel 75mg daily will be&#xD;
      maintained for 30 days. Flow-mediated dilation are performed at screening and at Visit 3 (day&#xD;
      30 from the treatment of study drugs) and blood sampling are performed before the first dose&#xD;
      of study drugs at Visit 2 and at Visit 3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in percent flow-mediated dilation (FMD) values</measure>
    <time_frame>Baseline, 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent flow-mediated dilation (FMD) values</measure>
    <time_frame>Baseline, 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of patient with percent flow-mediated dilation (FMD) value less than 7%</measure>
    <time_frame>Baseline, 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory gene expression levels by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR)</measure>
    <time_frame>Baseline, 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <condition>Vascular Inflammation</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 90mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 75mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 90mg twice daily for 30 days</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 75mg once daily for 30 days</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          -  Men and women ≥20 years of age&#xD;
&#xD;
          -  Documented history of non-ST-segment acute coronary syndrome occurring 30 ~ 365 days&#xD;
             prior to randomization and successfully treated with percutaneous coronary&#xD;
             intervention using drug-eluting stent&#xD;
&#xD;
          -  Patient currently prescribed and tolerating aspirin 100mg and clopidogrel 75mg.&#xD;
&#xD;
          -  Patient who have demonstrated endothelial dysfunction defined as percent flow-mediated&#xD;
             dilation values lower than 7% at baselines test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with angina related symptoms&#xD;
&#xD;
          -  Patients who did not undergo or failed invasive treatment&#xD;
&#xD;
          -  Patients with a history of hypersensitivity to ticagrelor or clopidogrel&#xD;
&#xD;
          -  Patients who took an anti-coagulant, anti-thrombotic regularly before the study, or&#xD;
             plan to have continuous treatment during the study&#xD;
&#xD;
          -  Patients who took vasoactive agents or caffeine ingestion for &lt;48&#xD;
&#xD;
          -  Patients with decompensated congestive heart failure of cardiogenic shock (Killip&#xD;
             classification III or IV)&#xD;
&#xD;
          -  Patients with intractable arrhythmia&#xD;
&#xD;
          -  Patients with intractable arrhythmia&#xD;
&#xD;
          -  Patients with second or third degree atrioventricular block&#xD;
&#xD;
          -  Patients with uncontrolled hypertension&#xD;
&#xD;
          -  Patients with high risk of hemorrhage like blood coagulation disorders,&#xD;
             gastrointestinal bleeding, gross hematuria, intraocular bleeding, hemorrhagic stroke,&#xD;
             intracranial hemorrhage&#xD;
&#xD;
          -  Patients with more than moderate chronic obstructive pulmonary disease diagnosed by&#xD;
             symptoms or documented by pulmonary function test&#xD;
&#xD;
          -  Patients who required renal replacement therapy&#xD;
&#xD;
          -  Patients with moderate to severe hepatic impairment&#xD;
&#xD;
          -  Patients with platelet &lt;100,000/μL&#xD;
&#xD;
          -  Patients with hematocrit &lt;30%&#xD;
&#xD;
          -  Concomitant oral or parenteral therapy with strong cytochrome P450 3A4 inhibitors,&#xD;
             cytochrome P450 3A substrates with narrow therapeutic indices, or strong cytochrome&#xD;
             P450 3A4 inducers i) Strong inhibitors: ketoconazole, itraconazole, voriconazole,&#xD;
             telithromycin, clarithromycin (but not erythromycin or azithromycin), nefazadone,&#xD;
             ritonavir, saquinavir, nelfinavir, indinavir, atanazavir, over 1 litre daily of&#xD;
             grapefruit juice ii) Substrates with narrow therapeutic index: cyclosporine,&#xD;
             quinidine, simvastatin at doses &gt;40 mg daily or lovastatin at doses &gt;40 mg daily iii)&#xD;
             Strong inducers: rifampin/rifampicin, rifabutin, phenytoin, carbamazepine,&#xD;
             phenobarbital&#xD;
&#xD;
          -  Patient who need to take drugs other than study medications and allowed concomitant&#xD;
             medications during study period.&#xD;
&#xD;
          -  Patients who have planned elective surgery or invasive procedure requiring temporary&#xD;
             discontinued study medication during study period.&#xD;
&#xD;
          -  Patients who are pregnant, breast feeding and not using medically acceptable birth&#xD;
             control.&#xD;
&#xD;
          -  Patients considered as unsuitable based on medical judgment by investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiyuk Chang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital, The Catholic.University of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kiyuk Chang, MD, PhD</last_name>
    <phone>82-2-2258-1139</phone>
    <email>kiyuk@catholic.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sungmin Lim, MD</last_name>
    <phone>82-2-2258-1139</phone>
    <email>sungmin@catholic.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital, The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiyuk Chang, MD, PhD</last_name>
      <phone>82-2-2258-1139</phone>
      <email>kiyuk@catholic.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Sungmin Lim, MD</last_name>
      <phone>82-2-2258-1139</phone>
      <email>sungmin@catholic.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Kiyuk Chang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sungmin Lim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eun Ho Choo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>February 28, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>July 3, 2016</last_update_submitted>
  <last_update_submitted_qc>July 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Kiyuk Chang</investigator_full_name>
    <investigator_title>Chief of the divison of cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

